louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01350895: Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group
Official title: Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Polycystic Ovary Syndrome
Keywords: Polycystic ovarian syndrome (PCOS)
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
First posted: 2011-05-10
Enrollment: 781
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 46
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Reproductive age women

Brief summary: To study the clinical and biochemical characteristics women with polycystic ovary syndrome (PCOS) in different aged groups.

Detailed description: Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder of reproductive age women, affecting an estimated 9-18% of all women in this age group. To diagnose of PCOS in early life is especially important because it is now thought to increase metabolic and cardiovascular risks. Investigating PCOS is crucial as it is now considered to increase metabolic and cardiovascular risk, thereby impacting the health of women to a much greater extent than previously thought. We are plan using retrospective analysis to evaluate the clinical and biochemical presentation of PCOS in different aged groups.

Eligibility criteria: Inclusion Criteria:

* Reproductive age women with sufficient data

Exclusion Criteria:

* Disorders of uterus (e.g. Asherman's Syndrome, Mullerian agenesis) and chromosomal anomalies (e.g. Turner syndrome)
* women who had had menarche at less than 3 years of age, Day 3 FSH \> 15, or who were older than 46
* women with inadequate clinical/biochemical records
* and women who had had ovarian cysts or ovarian tumors in ultrasonography examination
* pregnancy women

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University-WanFang Hospital
Study officials:
affiliation: Taipei Medical University WanFang Hospital
name: Ming-I Hsu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02722395: Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Official title: Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Liver Cancer
Metastatic Liver Cancer From Any Cancer Site
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2016-03-30
Enrollment: 5
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with stage I, II, III primary liver cancer Patients with metastatic liver cancer from any cancer site

Brief summary: This study is a research and development initiative established to explore the use of magnetic resonance imaging (MRI) as a tool for managing organ motion of the liver in cancer patients planning procedures for stereotactic body radiation therapy (SBRT).

Detailed description: There is a potential role to systematically implement MRI to establish appropriate workflow of the implementation for tumor motion management in liver SBRT. Compared to CT, MRI has many significant advantages for radiotherapy planning, including superior tumor and soft-tissue contrast, flexible imaging orientation, freedom from radiation exposure and real-time imaging. MRI solely based liver SBRT will allow for more precise delineation of target volume, less uncertainties in treatment planning, better motion management, and potentially better treatment outcome

Eligibility criteria: Inclusion Criteria:

* Age ≥ 21
* Patients with primary stage I, II, III liver cancer or metastatic tumor in the liver from any cancer site
* Signed, specific informed consent prior to study entry
* Women of child bearing potential must have a negative serum pregnancy test

Exclusion Criteria:

* Any condition for which a MRI procedure is contraindicated including presence of metallic material in the body, such as pacemakers, non- MRI compatible surgical clips, shrapnel.
* Pregnant or breast-feeding women are excluded.
* Subjects who have difficulty lying flat on their back for extended periods of time

Primary outcomes:
measure: Measure average motion trajectories
timeFrame: During MRI approx 1 hour
measure: Image quality, as measured by image rating
timeFrame: During MRI approx 1 hour
measure: Image quality, as measured by tumor volume
timeFrame: During MRI approx 1 hour
measure: Image quality, as measured by tumor-to-live contrast to noise ratio
timeFrame: During MRI approx 1 hour
measure: Planning target volume (PTV)
timeFrame: During MRI approx 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Brian Czito
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01643395: VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures
Official title: VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vertebral Compression Fracture
Spinal Trauma
Keywords: Trauma
vertebral
compression fracture
spinal
acute
vertebroplasty
conservative treatment
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2012-07-18
Enrollment: 99
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this protocol is to prove the efficacy of vertebroplasty in patients suffering from acute non osteoporotic vertebral compression fracture.

Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse.

Our study will compare vertebroplasty versus conservative therapy (brace).

Detailed description: The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification

Eligibility criteria: Inclusion Criteria:

* 18 - 70 year old
* volunteers
* Vertebral compression fractures Magerl type A
* Acute Trauma (less than 15 days)
* Between T5 and L5
* Patient able to undergo both vertebroplasty and conservative treatment
* Consent form obtained

Exclusion Criteria:

* Neural arch fracture
* C1 to T4 fracture
* Neurologic symptoms caused by the fracture
* Encephalic trauma with Glasgow Coma Scale less than 15
* Ongoing cancer
* Routine painkillers intake
* Local or systemic infection
* Coagulation's disorder
* Pregnancy
* Involvement in an another clinical trial

Primary outcomes:
measure: Disability scale
timeFrame: at 1 month
Secondary outcomes:
measure: Spine radiological measurements
timeFrame: at 1, 3 and 6 months
measure: Disability and qol
timeFrame: at 3 and 6 months
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Emmanuel CHABERT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01666795: Autoantibody Specificity and Response to IVIG in ITP
Official title: Autoantibody Specificity and Response to Intravenous Immunoglobulin G (IVIG) in Immune Thrombocytopenia (ITP): a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Immune Thrombocytopenia (ITP)
Lead sponsor: Shandong University
Sponsor class: OTHER
Collaborators: name: Second Affiliated Hospital of Medical College Shandong University
name: Jinan Military General Hospital
name: Shandong University of Traditional Chinese Medicine
name: West China Hospital
First posted: 2012-08-16
Enrollment: 672
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients with severe ITP who underwent IVIG therapy and had platelet autoantibodies assayed

Brief summary: The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.

Detailed description: Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder, in which platelet surface GPIIb/IIIa and GPIb/IX are the two most frequently targeted autoantigens. Our previous studies in animal models of ITP demonstrated that intravenous immunoglobulin G (IVIG) could protect against anti-GPIIb/IIIa-mediated thrombocytopenia but failed to ameliorate ITP induced by most anti-GPIb/IX antibodies. The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.

Eligibility criteria: Inclusion Criteria:

* (1) the diagnosis of ITP was based on the presence of isolated thrombocytopenia and the absence of any obvious initiating and/or underlying cause of the thrombocytopenia in accordance with the recently released international consensus guidelines,(2) a diagnosis was established during the 4 weeks prior to initiation of IVIG treatment, (3) age ≥ 18 years, (4) a platelet count of ≤ 20 × 109/L, and (5) a bleeding score ≥ 9 at the time of admission according to the clinical scoring system described by Khellaf et al. to assess the severity of hemorrhage.

Exclusion Criteria:

* a history of any ITP-specific treatment administered prior to or concomitantly with the IVIG

Primary outcomes:
measure: initial response
timeFrame: within 7 days of dosing
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital, Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital, Shandong University
name: Ming Hou, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, Xu RR, Guo CS, Wang XM, Cheng YF, Ni H, Hou M. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014 Apr;12(4):497-504. doi: 10.1111/jth.12524.
Clinical trial NCT04669795: Osteogenic Potential of Cissus Quadrangularis Alveolar Ridge Distraction
Official title: Evaluation of Osteogenic Potential of Cissus Quadrangularis on Mandibular Alveolar Ridge Distraction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Distraction of Bone
Dental Implant
Keywords: Alveolar
Bone
Distraction
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2020-12-17
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Deficient alveolar mandibular ridge corrected distraction osteogenesis to facilitate dental implant placement. Patients grouped into 2 groups: one group received Cissus quadrangularis during the consolidation period, and the other group received placebo.

Detailed description: OPGs were taken immediately after distractor placement, at end of activation period, at 1st,2nd month of consolidation period, and at end of consolidation period. Change in bone height was evaluated immediately after distractor placement, at end of activation and end of consolidation periods.

CBCT were taken immediately after implant installation, and 6 months later to evaluate change bone density and marginal bone level about the dental implant.

histological evaluation was done by biopsy obtained, by trephine bur, from implant site during its preparation. The bone biopsy fixed in 4% formalin solution for 7 days, rinsed in water, and dehydrated in sequent phases of ethanol (70, 80, 90, and 100%) and then specimens were stained by hematoxylin- eosin for microscopic evaluation.

Radiographic evaluation

Eligibility criteria: Inclusion Criteria:

* Patients were included if they were free from any disease that may affect healing. Also, presented with 2-3 missing teeth at least in posterior area and CBCT showed bone height above inferior alveolar canal (IAC) ranged 8-10mm.

Exclusion Criteria:

* patients were excluded if they suffered from any disease affect tissue healing, bad oral hygiene or heavy smoking patients

Primary outcomes:
measure: Bone gain after distraction
timeFrame: immediately at end of distractor activation
measure: Relapse after distraction
timeFrame: 3 months from beginning of consolidation period
measure: Crestal bone loss around dental implant
timeFrame: 6 months from implant placement
measure: Bone density around dental implant
timeFrame: 6 months from implant placement
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of dental medicine
state: Nasr City
Study officials:
affiliation: Al-Alharby university
name: Altaweel
role: PRINCIPAL_INVESTIGATOR
References:
citation: Altaweel AA, Baiomy AABA, Shoshan HS, Abbas H, Abdel-Hafiz AA, Gaber AE, Zewail AA, Elshiekh MAM. Evaluation of osteogenic potential of Cissus quadrangularis on mandibular alveolar ridge distraction. BMC Oral Health. 2021 Oct 4;21(1):491. doi: 10.1186/s12903-021-01847-y.
Clinical trial NCT00625495: Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Official title: An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Gastroesophageal Reflux Disease
Keywords: Gastroesophageal reflux disease
Nexium
Esomeprazole
Administration methods.
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-02-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).


Eligibility criteria: Inclusion Criteria:

* Heartburn on 2 out of the last 7 days prior to screening or a diagnosis of GERD (with or without a diagnosis of Erosive eosphagitis).
* Body Mass Index within the limits specified in the protocol

Exclusion Criteria:

* History of esophageal, duodenal or gastric surgery
* History of severe liver disease.
* Any other significant disease or pathology judged to be clinically significant by the investigator

Primary outcomes:
measure: To compare the maximum acid output during pentagastrin stimulation after 10 days of Nexium dosing administered orally with 10 days dosing via intravenous administration.
timeFrame: Every 10 days
Secondary outcomes:
measure: To compare basal acid output at steady state and when switching between Oral and IV adminstration of Nexium.
timeFrame: Post Day 10
measure: To compare maximum acid output when switching between Oral and IV adminstration of Nexium
timeFrame: Post Day 10
measure: Safety assessment via adverse event recording
timeFrame: At each visit
Other outcomes:
Locations:
Study officials:
affiliation: Nexium Global Product Director, AstraZeneca
name: Paula Fernstrom
role: STUDY_DIRECTOR
References:
Clinical trial NCT01106495: Effect of Enhanced External Counterpulsation (EECP) on Subclinical Atherosclerosis
Official title: Study of the Effect of EECP on Subclinical Atherosclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atherosclerosis
Keywords: Atherosclerosis
Vascular Endothelium
Counterpulsation, External
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2010-04-20
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Shear stress maybe the most crucial local factor affecting atherogenesis. The present study investigated the effect of exposure to increased shear stress promoted by Enhanced External Counterpulsation (EECP) on the progression of subclinical atherosclerosis and the underlying inflammation- related molecular mechanisms

Detailed description: Hypercholesterolemic subjects with subclinical atherosclerosis will be randomized into two groups: standard treatment group and standard treatment plus EECP intervention group. The results of ultrasound examination and markers of inflammations will be compared.

Eligibility criteria: Inclusion Criteria:

* 20- 70 years old subjects whose LDL higher than 160mg/dl and carotid intima-media thickness higher than 75 percent of his age.

Exclusion Criteria:

* Presence of history of coronary heart disease, stroke or atherosclerotic peripheral disease. Presence of impaired renal function, connective disease, or infectious disease.

Primary outcomes:
measure: Change in Intima-media thickness of the carotid artery
timeFrame: 7 weeks
Secondary outcomes:
measure: Change in vascular endothelial function
timeFrame: 7 weeks
measure: Change in serum markers of inflammation
timeFrame: 7 weeks
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Sun Yat- sen University
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Hong Ma, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05235295: Fluoroscopic vs Ultrasound Guided Sacroiliac (SI) Joint Injection
Official title: Fluoroscopic vs Ultrasound Guided Sacroiliac (SI) Joint Injection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Chronic
Lead sponsor: Diskapi Teaching and Research Hospital
Sponsor class: OTHER
First posted: 2022-02-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators aimed to evaluate the effectiveness of intra-articular sacroiliac joint injection under fluoroscopy versus ultrasound guidance


Eligibility criteria: Inclusion Criteria:

* Low back and/or gluteal pain without radicular extension for more than 3 months
* Tenderness over the SI joint
* Pain score \> 3 by Visual Analogue Scale

Exclusion Criteria:

* Malignancy
* Generalized or local infection
* Coagulopathy
* Allergy to drugs to be injected

Primary outcomes:
measure: Reduction in pain
timeFrame: Change from baseline pain score at 3 months
Secondary outcomes:
measure: Oswestry Disability Index (ODI)
timeFrame: Baseline to 3 months post-procedure
measure: Patient satisfaction Questionnaire
timeFrame: baseline to 3 months post-procedure
measure: Quantitative analgesic questionnaire
timeFrame: at 3 months post-procedure
measure: Procedure time
timeFrame: Intraoperative
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Diskapi Yildirim Beyazit Training and Research Hospital
Study officials:
References:
Clinical trial NCT01539395: A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
Official title: A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Multiple Sclerosis
Keywords: Relapsing Remitting
MS
Lead sponsor: MSDx, Inc.
Sponsor class: INDUSTRY
First posted: 2012-02-27
Enrollment: 0
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who currently diagnosed with relapsing remitting multiple sclerosis

Brief summary: This is a Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis.


Eligibility criteria: Inclusion Criteria:

1. Age 45 years or older of either gender and of any racial/ethnic group.
2. Subjects must be in generally good health.
3. Subjects must be able and willing to comply with the requirements of the protocol.
4. Must be diagnosed with RRMS
5. Meets the criteria to enter Group 1 or Group 2

Exclusion Criteria:

1. Subject is currently in middle of an active episode of an autoimmune condition (e.g. rheumatoid arthritis, system lupus erythematosis)
2. Subject currently has a condition such as active influenza that would stimulate the immune system

Primary outcomes:
measure: Biomarker Differential
timeFrame: Baseline
Secondary outcomes:
measure: Biomarker reduction with steroid therapy
timeFrame: 3 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Northwest NeuroSpecialists, PLLC
state: Arizona
Study officials:
affiliation: Northwest NeuroSpecialists, PLLC
name: Jeanette K Wendt, MD
role: PRINCIPAL_INVESTIGATOR
References: